Tatsis Fotios, Dragioti Elena, Gouva Mary, Koulouras Vasilios
Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, GRC.
Research Laboratory Psychology of Patients, Families & Health Professionals, Department of Nursing, School of Health Sciences, University of Ioannina, Ioannina, GRC.
Cureus. 2023 Jul 13;15(7):e41802. doi: 10.7759/cureus.41802. eCollection 2023 Jul.
The impact of the coronavirus disease 2019 (COVID-19) pandemic on the global economy is far-reaching and difficult to assess accurately. We aimed to systematically determine the magnitude of the costs and the economic burden of intensive care for hospitalized COVID-19 patients since the onset of the pandemic by means of a systematic review. We conducted a PRISMA 2020-compliant (protocol: PROSPERO CRD42022348741) systematic review by searching PubMed, EMBASE, and Web of Science for relevant literature. We included studies that presented costs based on a primary partial economic evaluation. Using the Consolidated Health Economic Evaluation Reporting Standards checklist and the population, intervention, control, and outcome criteria, we established the risk of bias in studies at the individual level. Daily cost per ICU admission and total cost per ICU patient of the original studies extracted. A random effect model was adopted for meta-analysis whenever possible. Of the 1,635 unique records identified, 14 studies related to ICU-hospitalized costs due to COVID-19 were eligible for inclusion. Included studies represented 93,721 hospitalized COVID-19 patients. Regarding total direct medical costs, the lowest cost per patient at ICU was observed in Turkey ($2,984.78 ± 2,395.93), while the highest was in Portugal ($51,358.52 ± 30,150.38). The Republic of Korea reported the highest length of stay of 29.4 days (±17.80), and the lowest is observed in India for nine days (±5.98). Our findings emphasize COVID-19's significance on health-economic outcomes. Limited research exists on the economic burden of COVID-19 in the ICU. Further studies on cost estimates can enhance data clarity, enabling informed analysis of healthcare costs and aiding efficient patient care organization by care providers and policymakers.
2019年冠状病毒病（COVID-19）大流行对全球经济的影响深远，难以准确评估。我们旨在通过系统评价，系统地确定自大流行开始以来，住院COVID-19患者重症监护的成本规模和经济负担。我们按照PRISMA 2020（方案：PROSPERO CRD42022348741）进行系统评价，通过检索PubMed、EMBASE和科学网查找相关文献。我们纳入了基于初步部分经济评估呈现成本的研究。使用《卫生经济评估报告标准合并清单》以及人群、干预措施、对照和结局标准，我们在个体层面确定了研究中的偏倚风险。提取原始研究中每次ICU入院的每日成本和每位ICU患者的总成本。尽可能采用随机效应模型进行荟萃分析。在识别出的1635条独特记录中，14项与COVID-19导致的ICU住院成本相关的研究符合纳入标准。纳入的研究代表了93721例住院的COVID-19患者。关于总直接医疗成本，ICU中每位患者成本最低的是土耳其（2984.78美元±2395.93美元），而最高的是葡萄牙（51358.52美元±30150.38美元）。韩国报告的住院时间最长，为29.4天（±17.80天），印度最短，为9天（±5.98天）。我们的研究结果强调了COVID-19对卫生经济结局的重要性。关于COVID-19在ICU中的经济负担的研究有限。进一步的成本估算研究可以提高数据清晰度，有助于医疗服务提供者和政策制定者对医疗成本进行明智分析，并有助于高效地组织患者护理。
